Belite Bio, Inc
BLTE
Rangering i aksjer
#3051
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Aksjekurs
$148.24
Sist synkronisert: 2026-10-19
Markedsverdi
$5.97B
Endring (1 dag)
3.82%
Endring (1 år)
64.04%
Land
US
Handel Belite Bio, Inc (BLTE)
Kategori
Healthcare
Historikk for aksjesplitt for Belite Bio, Inc (BLTE)
Aksjen Belite Bio, Inc (symbol: BLTE) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 20, 2026.
Én BLTE-aksje kjøpt før Oct 20, 2026 tilsvarer i dag 0 BLTE-aksjer.
Den nyeste splittelsen skjedde Oct 20, 2026.
Én BLTE-aksje kjøpt før Oct 20, 2026 tilsvarer i dag 0 BLTE-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
